Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Denali Therapeutics Inc.DNLI · Entity 1735 | COFO and Secretary | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Denali Therapeutics Inc.
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 278,995 |
Reported balance
After 2026-09-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-01 · Sale · Disposed 2,768 · Balance 278,995 F1: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted March 27, 2026. F2: Includes 135,475 Unvested RSUs. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 523,749 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 523,749 F3: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted March 27, 2026.
F2: Includes 135,475 Unvested RSUs.
F3: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 3, 2026 20:17 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,768 | $23.44 | $64,881.92 |
DisclosureSEC source: 0001724311-26-000014 · wk-form4_1788466654.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 278,995 F1 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted March 27, 2026. F2 · balance_after: Includes 135,475 Unvested RSUs. Read SEC document |
| August 11, 2026 Filed Aug 13, 2026 21:01 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,857 | $25.07 | $71,624.99 |
DisclosureSEC source: 0001724311-26-000013 · wk-form4_1786654917.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 281,763 F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested RSUs. F2 · balance_after: Includes 135,475 Unvested RSUs. F3 · balance_after: Includes 1,792 shares acquired under the ESPP Purchase on June 1, 2026. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:19 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 17,218 | $16.50 | $284,097.00 |
DisclosureSEC source: 0001724311-26-000005 · wk-form4_1767907181.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 282,828 F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested RSUs. F2 · balance_after: Includes 141,100 Unvested RSUs. Read SEC document |
| January 03, 2026 Filed Jan 5, 2026 23:49 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 173,100 | $0.00 Strike: $16.27 | $0.00 |
DisclosureSEC source: 0001724311-26-000001 · wk-form4_1767656950.xml · derivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,100 Underlying: Common Stock · 173,100 shares Expires 2036-01-03 F4 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 3, 2027, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| January 03, 2026 Filed Jan 5, 2026 23:49 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 57,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001724311-26-000001 · wk-form4_1767656950.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,046 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2027 (the "Vesting Commencement Date") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · balance_after: Includes 141,100 Unvested RSUs. Read SEC document |
| August 12, 2025 Filed Aug 15, 2025 00:33 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,937 | $13.58 | $39,884.46 |
DisclosureSEC source: 0001724311-25-000011 · wk-form4_1755218026.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 242,346 F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $13.35 to $13.58 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 128,405 Unvested RSUs. F4 · balance_after: Includes 975 shares acquired under the ESPP Purchase on June 2, 2025. Read SEC document |
| January 07, 2025 Filed Jan 9, 2025 01:25 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,907 | $20.81 | $60,494.67 |
DisclosureSEC source: 0001714899-25-000050 · wk-form4_1736385937.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 244,308 F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units. F3 · balance_after: Includes 134,030 Unvested RSUs. Read SEC document |
| January 06, 2025 Filed Jan 9, 2025 01:25 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 12,255 | $20.22 | $247,796.10 |
DisclosureSEC source: 0001714899-25-000050 · wk-form4_1736385937.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 247,215 F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $19.91 to $20.23 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 134,030 Unvested RSUs. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 23:57 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 162,540 | $0.00 Strike: $21.26 | $0.00 |
DisclosureSEC source: 0001714899-25-000027 · wk-form4_1736294268.xml · derivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,540 Underlying: Common Stock · 162,540 shares Expires 2035-01-02 F4 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 3, 2026, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 23:57 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 54,180 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-25-000027 · wk-form4_1736294268.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 259,470 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2026 (the "Vesting Commencement Date") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · balance_after: Includes 141,530 Unvested RSUs. Read SEC document |
| December 27, 2024 Filed Dec 31, 2024 21:18 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 6,708 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001714899-24-000236 · wk-form4_1735679885.xml · derivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,671 Underlying: Common Stock · 6,708 shares Expires 2027-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
| December 27, 2024 Filed Dec 31, 2024 21:18 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 6,708 | $5.28 | $35,418.24 |
DisclosureSEC source: 0001714899-24-000236 · wk-form4_1735679885.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 118,810 Unvested RSUs. Read SEC document |
| November 22, 2024 Filed Nov 26, 2024 22:19 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 20,516 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001714899-24-000234 · wk-form4_1732659560.xml · derivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,562 Underlying: Common Stock · 20,516 shares Expires 2025-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days. Read SEC document |
| November 22, 2024 Filed Nov 26, 2024 22:19 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 20,516 | $0.68 | $13,950.88 |
DisclosureSEC source: 0001714899-24-000234 · wk-form4_1732659560.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,582 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: Includes 118,810 Unvested RSUs. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 21:44 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 15,558 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001714899-24-000218 · wk-form4_1731447884.xml · derivative · entry 6 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,379 Underlying: Common Stock · 15,558 shares Expires 2027-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 21:44 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 300 | $31.29 | $9,387.00 |
DisclosureSEC source: 0001714899-24-000218 · wk-form4_1731447884.xml · nonDerivative · entry 4 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,066 F2 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 29, 2023. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $31.27 to $31.30 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F1 · balance_after: Includes 118,810 Unvested RSUs. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 21:44 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,925 | $30.72 | $89,856.00 |
DisclosureSEC source: 0001714899-24-000218 · wk-form4_1731447884.xml · nonDerivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,366 F2 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 29, 2023. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.21 to $31.17 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F1 · balance_after: Includes 118,810 Unvested RSUs. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 21:44 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 12,333 | $29.68 | $366,043.44 |
DisclosureSEC source: 0001714899-24-000218 · wk-form4_1731447884.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 181,291 F2 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 29, 2023. F3 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $29.21 to $30.20 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F1 · balance_after: Includes 118,810 Unvested RSUs. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 21:44 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 15,558 | $5.28 | $82,146.24 |
DisclosureSEC source: 0001714899-24-000218 · wk-form4_1731447884.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 193,624 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 118,810 Unvested RSUs. Read SEC document |
| August 21, 2024 Filed Aug 22, 2024 20:14 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,547 | $24.78 | $63,114.66 |
DisclosureSEC source: 0001714899-24-000195 · wk-form4_1724357674.xml · nonDerivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,066 F3 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 29, 2023. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $24.19 to $25.07 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes 118,810 Unvested RSUs. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:14 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 3,353 | $23.54 | $78,929.62 |
DisclosureSEC source: 0001714899-24-000195 · wk-form4_1724357674.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 180,613 F3 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 29, 2023. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $23.38 to $23.72 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes 118,810 Unvested RSUs. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:14 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,453 | $23.79 | $58,356.87 |
DisclosureSEC source: 0001714899-24-000195 · wk-form4_1724357674.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 183,966 F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units. F2 · balance_after: Includes 118,810 Unvested RSUs. Read SEC document |
| August 13, 2024 Filed Aug 15, 2024 20:10 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,272 | $22.89 | $52,006.08 |
DisclosureSEC source: 0001714899-24-000177 · wk-form4_1723752595.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,419 F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units. F2 · balance_after: Includes 123,810 RSUs. F3 · balance_after: Includes 1,350 shares acquired under the ESPP Purchase on May 31, 2024. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 02:14 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 20,128 | $17.66 | $355,460.48 |
DisclosureSEC source: 0001714899-24-000059 · wk-form4_1708049627.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,341 F4 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 29, 2023. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $17.08 to $17.97 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 129,435 RSUs. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 02:14 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,716 | $17.29 | $46,959.64 |
DisclosureSEC source: 0001714899-24-000059 · wk-form4_1708049627.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 207,469 F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $17.08 to $17.30 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 129,435 RSUs. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 21:48 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001714899-24-000042 · wk-form4_1707774481.xml · derivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,078 Underlying: Common Stock · 50,000 shares Expires 2025-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 21:48 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 50,000 | $0.68 | $34,000.00 |
DisclosureSEC source: 0001714899-24-000042 · wk-form4_1707774481.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,185 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 136,721 RSUs. F2 · balance_after: Reflects 15,558 shares previously disclosed as held indirectly; but have been determined to be held directly. Read SEC document |
| January 05, 2024 Filed Jan 10, 2024 00:34 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 9,972 | $19.43 | $193,755.96 |
DisclosureSEC source: 0001714899-24-000036 · wk-form4_1704846835.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 539,307 F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $19.36 to $19.43 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects the issuance of shares to The Schuth Family Trust U/A DTD 06/05/2017 in connection with the vesting of 25,530 RSUs held by the Reporting Person. F4 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 22:57 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 161,160 | $0.00 Strike: $20.33 | $0.00 |
DisclosureSEC source: 0001714899-24-000010 · wk-form4_1704495454.xml · derivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,160 Underlying: Common Stock · 161,160 shares Expires 2034-01-02 F5 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 3, 2025, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 22:57 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 53,720 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-24-000010 · wk-form4_1704495454.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,157 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2025 (the "Vesting Commencement Date") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · balance_after: Includes 136,721 RSU's as of January 4, 2024. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 21:36 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,522 | $23.17 | $58,434.74 |
DisclosureSEC source: 0001714899-23-000137 · wk-form4_1692999400.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 518,989 F1 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 30, 2022. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $22.87 to $23.36 per share. Upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| August 21, 2023 Filed Aug 23, 2023 20:33 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,478 | $22.59 | $55,978.02 |
DisclosureSEC source: 0001714899-23-000134 · wk-form4_1692822802.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 521,511 F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $22.49 to $23.00 per share. Upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects the issuance of shares to The Schuth Family Trust U/A DTD 06/05/2017 in connection with the vesting of 5,000 RSUs held by the Reporting Person. F4 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 22:19 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,772 | $23.67 | $65,613.24 |
DisclosureSEC source: 0001714899-23-000124 · wk-form4_1692224345.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 518,989 F1 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 30, 2022. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $23.58 to $23.80 per share. Upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 21:11 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,853 | $24.18 | $68,985.54 |
DisclosureSEC source: 0001714899-23-000121 · wk-form4_1692047483.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 521,761 F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units. F2 · price: . The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $23.99 to $24.35 per share. Upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects the issuance of shares to The Schuth Family Trust U/A DTD 06/05/2017 in connection with the vesting of 5,625 RSUs held by the Reporting Person. F4 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| July 18, 2023 Filed Jul 19, 2023 21:10 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 9,702 | $30.01 | $291,157.02 |
DisclosureSEC source: 0001714899-23-000109 · wk-form4_1689801007.xml · nonDerivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 518,989 F3 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 30, 2022. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.00 to $30.04 per share. Upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 21:10 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001714899-23-000109 · wk-form4_1689801007.xml · derivative · entry 5 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,937 Underlying: Common Stock · 10,000 shares Expires 2027-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vested monthly thereafter. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 21:10 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 10,000 | $29.60 | $296,000.00 |
DisclosureSEC source: 0001714899-23-000109 · wk-form4_1689801007.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 528,691 F3 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 30, 2022. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $29.33 to $29.94 per share. Upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 21:10 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 10,000 | $5.28 | $52,800.00 |
DisclosureSEC source: 0001714899-23-000109 · wk-form4_1689801007.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 538,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Exercised shares were issued to the Schuth Family Trust. F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:56 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001714899-23-000076 · wf-form4_168435700588836.xml · derivative · entry 5 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,937 Underlying: Common Stock · 10,000 shares Expires 2027-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vested monthly thereafter. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:56 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 800 | $29.23 | $23,384.00 |
DisclosureSEC source: 0001714899-23-000076 · wf-form4_168435700588836.xml · nonDerivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 528,691 F3 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 30, 2022. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $29.20 to $29.25 per share. Upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:56 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 9,200 | $28.55 | $262,660.00 |
DisclosureSEC source: 0001714899-23-000076 · wf-form4_168435700588836.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 529,491 F3 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 30, 2022. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $28.15 to $29.07 per share. Upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:56 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 10,000 | $5.28 | $52,800.00 |
DisclosureSEC source: 0001714899-23-000076 · wf-form4_168435700588836.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 538,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Exercised shares were issued to the Schuth Family Trust. F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| April 13, 2023 Filed Apr 14, 2023 22:27 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 4,898 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001714899-23-000055 · wf-form4_168151121787982.xml · derivative · entry 7 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,937 Underlying: Common Stock · 4,898 shares Expires 2027-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vested monthly thereafter. Read SEC document |
| April 13, 2023 Filed Apr 14, 2023 22:27 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 4,898 | $25.04 | $122,645.92 |
DisclosureSEC source: 0001714899-23-000055 · wf-form4_168151121787982.xml · nonDerivative · entry 4 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 528,691 F3 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 30, 2022. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $25.00 to $25.10 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| April 13, 2023 Filed Apr 14, 2023 22:27 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 4,898 | $5.28 | $25,861.44 |
DisclosureSEC source: 0001714899-23-000055 · wf-form4_168151121787982.xml · nonDerivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 533,589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Exercised shares were issued to the Schuth Family Trust. F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 22:27 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 5,102 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001714899-23-000055 · wf-form4_168151121787982.xml · derivative · entry 6 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,835 Underlying: Common Stock · 5,102 shares Expires 2027-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vested monthly thereafter. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 22:27 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 5,102 | $25.04 | $127,754.08 |
DisclosureSEC source: 0001714899-23-000055 · wf-form4_168151121787982.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 528,691 F3 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 30, 2022. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $25.00 to $25.49 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 22:27 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 5,102 | $5.28 | $26,938.56 |
DisclosureSEC source: 0001714899-23-000055 · wf-form4_168151121787982.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 533,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Exercised shares were issued to the Schuth Family Trust. F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 00:01 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001714899-23-000030 · wf-form4_167650569228111.xml · derivative · entry 4 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,078 Underlying: Common Stock · 25,000 shares Expires 2025-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days. Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 00:01 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 3,497 | $30.09 | $105,224.73 |
DisclosureSEC source: 0001714899-23-000030 · wf-form4_167650569228111.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COFO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 528,691 F3 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $29.92 to $30.24 per share. Upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F5 · balance_after: Reflects the issuance of shares to The Schuth Family Trust U/A DTD 06/05/2017 in connection with the vesting of 7,286 RSUs held by the Reporting Person. F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.